No. 02 | The science of software infrastructure | The second post in our thought leadership series.
No. 01 | The science of software infrastructure | The first post in our thought leadership series.
PIHS is using Torx® to bring together chemists, biologists, computational scientists, and project managers to work more efficiently.
Elixir Software Limited is delighted to announce the appointment of Nicola Dennis to the newly created role of Head of Global Sales.
How iTraX significantly improved efficiency for toxicology and bioanalytical study management in a mid-sized biotech company.
AstraZeneca and Elixir Software unveiled a groundbreaking integrated analytical workflow management tool, at SLAS Boston 2024.
From streamlining R&D workflows and collaboration with data-driven software platforms, to building tools that make the development of new therapies possible, to empowering more efficient and inclusive clinical trials, these companies are laying the foundations for a new era of life science and digital technology innovations.
A US-based global biotechnology company had a commonly seen challenge in Laboratory Animal Science (LAS). Biopharmaceutical LAS teams receive multiple project requests for studies and need to schedule the delivery of tasks by relevant skilled technicians, with the available and designated time slots. In conversation with their clients, Elixir learned that many of the currently available tools used for LAS are disconnected and inefficient for effective study planning, tracking and delivery. The use of multiple emails, calendars and isolated files e.g., spreadsheets has resulted in a complex process, that is typically maintained through time-consuming daily meetings.
This clinical-stage biopharmaceutical company’s chemistry engine combined in-house medicinal chemistry design with external synthesis capabilities. It was critical for them to have a robust process for tracking the design cycle (Design-Make-Test-Analyze) to assure expedient execution and quality decision making. A specific technical challenge, common to many institutions, is unambiguous tracking of synthetic targets across multiple projects and partners. Issues may and do arise from keeping track of the target status, changes in the target priority, and other synthetic queue modifications.In common with many growing biotech companies, a Boston-based biotech augments its in-house chemistry team with tens of synthetic chemists from multiple CRO partners. While this enables the company to significantly increase its capacity, it also brings the challenge of coordinating work between multiple organizations around the globe.
How iTraX significantly improved efficiency for toxicology and bioanalytical study management in a mid-sized biotech company.
A US-based global biotechnology company had a commonly seen challenge in Laboratory Animal Science (LAS). Biopharmaceutical LAS teams receive multiple project requests for studies and need to schedule the delivery of tasks by relevant skilled technicians, with the available and designated time slots. In conversation with their clients, Elixir learned that many of the currently available tools used for LAS are disconnected and inefficient for effective study planning, tracking and delivery. The use of multiple emails, calendars and isolated files e.g., spreadsheets has resulted in a complex process, that is typically maintained through time-consuming daily meetings.
This clinical-stage biopharmaceutical company’s chemistry engine combined in-house medicinal chemistry design with external synthesis capabilities. It was critical for them to have a robust process for tracking the design cycle (Design-Make-Test-Analyze) to assure expedient execution and quality decision making. A specific technical challenge, common to many institutions, is unambiguous tracking of synthetic targets across multiple projects and partners. Issues may and do arise from keeping track of the target status, changes in the target priority, and other synthetic queue modifications.In common with many growing biotech companies, a Boston-based biotech augments its in-house chemistry team with tens of synthetic chemists from multiple CRO partners. While this enables the company to significantly increase its capacity, it also brings the challenge of coordinating work between multiple organizations around the globe.
How iTraX significantly improved efficiency for toxicology and bioanalytical study management in a mid-sized biotech company.
A US-based global biotechnology company had a commonly seen challenge in Laboratory Animal Science (LAS). Biopharmaceutical LAS teams receive multiple project requests for studies and need to schedule the delivery of tasks by relevant skilled technicians, with the available and designated time slots. In conversation with their clients, Elixir learned that many of the currently available tools used for LAS are disconnected and inefficient for effective study planning, tracking and delivery. The use of multiple emails, calendars and isolated files e.g., spreadsheets has resulted in a complex process, that is typically maintained through time-consuming daily meetings.
This clinical-stage biopharmaceutical company’s chemistry engine combined in-house medicinal chemistry design with external synthesis capabilities. It was critical for them to have a robust process for tracking the design cycle (Design-Make-Test-Analyze) to assure expedient execution and quality decision making. A specific technical challenge, common to many institutions, is unambiguous tracking of synthetic targets across multiple projects and partners. Issues may and do arise from keeping track of the target status, changes in the target priority, and other synthetic queue modifications.In common with many growing biotech companies, a Boston-based biotech augments its in-house chemistry team with tens of synthetic chemists from multiple CRO partners. While this enables the company to significantly increase its capacity, it also brings the challenge of coordinating work between multiple organizations around the globe.
This clinical-stage biopharmaceutical company’s chemistry engine combined in-house medicinal chemistry design with external synthesis capabilities. It was critical for them to have a robust process for tracking the design cycle (Design-Make-Test-Analyze) to assure expedient execution and quality decision making. A specific technical challenge, common to many institutions, is unambiguous tracking of synthetic targets across multiple projects and partners. Issues may and do arise from keeping track of the target status, changes in the target priority, and other synthetic queue modifications.
